Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Belite Bio, Inc - American Depositary Shares (NQ:BLTE)

56.88 -7.15 (-11.16%)
Streaming Delayed Price Updated: 1:15 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 58,371
Open 64.00
Bid (Size) 56.39 (2)
Ask (Size) 57.38 (1)
Prev. Close 64.03
Today's Range 55.00 - 64.12
52wk Range 31.00 - 86.53
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Belite Bio Analysts See Potential For Stock Gains With Progress In Key Trials
Belite Bio Inc (NASDAQ: BLTE) stock falls after reporting Q3 net loss of $36.1M; analysts maintain Buy/Overweight rating, citing positive trial results. 
Via Benzinga
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
From Belite Bio, Inc
Via GlobeNewswire

Performance

YTD
-12.2%
-12.2%
1 Month
-4.9%
-4.9%
3 Month
-12.2%
-12.2%
6 Month
+11.8%
+11.8%
1 Year
+41.0%
+41.0%

More News

Read More
Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
Earnings Scheduled For November 12, 2024
Via Benzinga
Insights into Belite Bio's Upcoming Earnings
Via Benzinga
Earnings Scheduled For March 17, 2025
Via Benzinga
Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Participate in the Leerink Partners Global Healthcare Conference
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Announces Registered Direct Offering of $15 Million
From Belite Bio, Inc
Via GlobeNewswire
Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007
From Lin BioScience, Inc.
Via GlobeNewswire
Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease
From Belite Bio, Inc
Via GlobeNewswire
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
Belite Bio to Participate in Three Upcoming Investor Conferences
From Belite Bio, Inc
Via GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024
From Virtual Investor Conferences
Via GlobeNewswire
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
From Belite Bio, Inc
Via GlobeNewswire
BLTE Stock Earnings: Belite Bio Misses EPS for Q2 2024
Via InvestorPlace
Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results
From Belite Bio, Inc
Via GlobeNewswire

Frequently Asked Questions

Is Belite Bio, Inc - American Depositary Shares publicly traded?
Yes, Belite Bio, Inc - American Depositary Shares is publicly traded.
What exchange does Belite Bio, Inc - American Depositary Shares trade on?
Belite Bio, Inc - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Belite Bio, Inc - American Depositary Shares?
The ticker symbol for Belite Bio, Inc - American Depositary Shares is BLTE on the Nasdaq Stock Market
What is the current price of Belite Bio, Inc - American Depositary Shares?
The current price of Belite Bio, Inc - American Depositary Shares is 56.88
When was Belite Bio, Inc - American Depositary Shares last traded?
The last trade of Belite Bio, Inc - American Depositary Shares was at 04/04/25 01:15 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.